GSK Acquires Syndivia's Prostate Cancer ADC for £268m
GSK has acquired the rights to Syndivia's preclinical antibody drug conjugate (ADC) for £268m, despite having its own ADC in development for prostate cancer.
This move fuels the industry buzz for the promising anti-tumour modality.
The gold standard of business intelligence.
GSK is doubling down on the modality, combining business intelligence and editorial excellence to reach engaged professionals.
Author's summary: GSK buys Syndivia's ADC for £268m.